接受他汀类药物治疗的日本稳定型心绞痛患者经皮冠状动脉介入治疗后,估计的小致密低密度脂蛋白胆固醇与新病变发生率之间的关系

IF 1.9 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Reviews in cardiovascular medicine Pub Date : 2024-06-17 eCollection Date: 2024-06-01 DOI:10.31083/j.rcm2506218
Daisuke Kanda, Akihiro Tokushige, Mitsuru Ohishi
{"title":"接受他汀类药物治疗的日本稳定型心绞痛患者经皮冠状动脉介入治疗后,估计的小致密低密度脂蛋白胆固醇与新病变发生率之间的关系","authors":"Daisuke Kanda, Akihiro Tokushige, Mitsuru Ohishi","doi":"10.31083/j.rcm2506218","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Low-density lipoprotein cholesterol (LDL-C) is considered the most important risk factor for coronary artery disease (CAD). Although lipid-lowering therapy using high-intensity statins for patients with stable CAD is one of the cornerstones of medication therapy, there is still a risk of residual cardiovascular events, even after controlling for LDL-C. Recently, attention has focused on the association between small dense LDL-C as a residual risk factor for CAD, and it has been reported that a formula can be used to calculate the small LDL-C.</p><p><strong>Methods: </strong>We investigated the association between estimated small dense LDL-C (Esd LDL-C) and the occurrence of new lesions with myocardial ischemia <math><mo>≤</mo></math> 2 years after percutaneous coronary intervention (PCI) in 537 patients with stable angina who underwent PCI. In this study, all patients had been prescribed statins. This study was based on previously reported data regarding the relationship between non-high-density lipoprotein cholesterol levels and stable angina pectoris after PCI.</p><p><strong>Results: </strong>Revascularization, including new lesions and in-stent restenosis, and new lesions appeared in 130 and 90 patients, respectively, <math><mo>≤</mo></math> 2 years after PCI. Age, diabetes mellitus (DM), LDL-C, and Esd LDL-C were associated with the occurrence of revascularization and new lesions <math><mo>≤</mo></math> 2 years after PCI. Multivariate logistic regression analysis models revealed that Esd LDL-C [odds ratio (OR) 1.03, 95% confidence interval (CI) 1.004-1.048, <i>p</i> = 0.020; and OR 1.03, 95% CI 1.009-1.057, <i>p</i> = 0.007, respectively] were associated with the revascularization and occurrence of new lesions <math><mo>≤</mo></math> 2 years after PCI.</p><p><strong>Conclusions: </strong>As well as total cholesterol and LDL-C, Esd LDL-C was an independent risk factor for the revascularization and occurrence of new lesions <math><mo>≤</mo></math> 2 years after PCI for stable angina in Japanese patients receiving statin therapy. In patients with stable angina who are on lipid-lowering therapy with statins, calculating the Esd LDL-C may provide useful information for predicting revascularization and the occurrence of new lesions.</p>","PeriodicalId":20989,"journal":{"name":"Reviews in cardiovascular medicine","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270076/pdf/","citationCount":"0","resultStr":"{\"title\":\"Association between Estimated Small Dense Low-Density Lipoprotein Cholesterol and Occurrence of New Lesions after Percutaneous Coronary Intervention in Japanese Patients with Stable Angina and Receiving Statin Therapy.\",\"authors\":\"Daisuke Kanda, Akihiro Tokushige, Mitsuru Ohishi\",\"doi\":\"10.31083/j.rcm2506218\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Low-density lipoprotein cholesterol (LDL-C) is considered the most important risk factor for coronary artery disease (CAD). Although lipid-lowering therapy using high-intensity statins for patients with stable CAD is one of the cornerstones of medication therapy, there is still a risk of residual cardiovascular events, even after controlling for LDL-C. Recently, attention has focused on the association between small dense LDL-C as a residual risk factor for CAD, and it has been reported that a formula can be used to calculate the small LDL-C.</p><p><strong>Methods: </strong>We investigated the association between estimated small dense LDL-C (Esd LDL-C) and the occurrence of new lesions with myocardial ischemia <math><mo>≤</mo></math> 2 years after percutaneous coronary intervention (PCI) in 537 patients with stable angina who underwent PCI. In this study, all patients had been prescribed statins. This study was based on previously reported data regarding the relationship between non-high-density lipoprotein cholesterol levels and stable angina pectoris after PCI.</p><p><strong>Results: </strong>Revascularization, including new lesions and in-stent restenosis, and new lesions appeared in 130 and 90 patients, respectively, <math><mo>≤</mo></math> 2 years after PCI. Age, diabetes mellitus (DM), LDL-C, and Esd LDL-C were associated with the occurrence of revascularization and new lesions <math><mo>≤</mo></math> 2 years after PCI. Multivariate logistic regression analysis models revealed that Esd LDL-C [odds ratio (OR) 1.03, 95% confidence interval (CI) 1.004-1.048, <i>p</i> = 0.020; and OR 1.03, 95% CI 1.009-1.057, <i>p</i> = 0.007, respectively] were associated with the revascularization and occurrence of new lesions <math><mo>≤</mo></math> 2 years after PCI.</p><p><strong>Conclusions: </strong>As well as total cholesterol and LDL-C, Esd LDL-C was an independent risk factor for the revascularization and occurrence of new lesions <math><mo>≤</mo></math> 2 years after PCI for stable angina in Japanese patients receiving statin therapy. In patients with stable angina who are on lipid-lowering therapy with statins, calculating the Esd LDL-C may provide useful information for predicting revascularization and the occurrence of new lesions.</p>\",\"PeriodicalId\":20989,\"journal\":{\"name\":\"Reviews in cardiovascular medicine\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-06-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11270076/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Reviews in cardiovascular medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.31083/j.rcm2506218\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"CARDIAC & CARDIOVASCULAR SYSTEMS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in cardiovascular medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.31083/j.rcm2506218","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

摘要

背景:低密度脂蛋白胆固醇(LDL-C低密度脂蛋白胆固醇(LDL-C)被认为是冠状动脉疾病(CAD)最重要的危险因素。尽管使用高强度他汀类药物对稳定型 CAD 患者进行降脂治疗是药物治疗的基石之一,但即使控制了低密度脂蛋白胆固醇,仍有发生残余心血管事件的风险。最近,人们开始关注小密度低密度脂蛋白胆固醇(LDL-C)作为一种残余的心血管疾病危险因素之间的关联,有报道称可以使用一种公式来计算小密度低密度脂蛋白胆固醇(LDL-C):我们对 537 名接受了经皮冠状动脉介入治疗(PCI)的稳定型心绞痛患者进行了研究,探讨了估计的小密度低密度脂蛋白胆固醇(Esd LDL-C)与经皮冠状动脉介入治疗(PCI)后 2 年内发生新病变和心肌缺血之间的关系。在这项研究中,所有患者都服用了他汀类药物。这项研究基于之前报告的有关PCI术后非高密度脂蛋白胆固醇水平与稳定型心绞痛之间关系的数据:结果:PCI术后2年以内,分别有130名和90名患者出现血管再通(包括新病变和支架内再狭窄)和新病变。年龄、糖尿病(DM)、低密度脂蛋白胆固醇(LDL-C)和Esd LDL-C与PCI术后2年内血管再通和新病变的发生有关。多变量逻辑回归分析模型显示,Esd LDL-C[odds ratio (OR) 1.03,95% confidence interval (CI) 1.004-1.048,p = 0.020;OR 1.03,95% CI 1.009-1.057,p = 0.007]与PCI术后≤2年的血管再通和新病变的发生有关:结论:在接受他汀类药物治疗的日本稳定型心绞痛患者中,除了总胆固醇和低密度脂蛋白胆固醇外,Esd低密度脂蛋白胆固醇也是PCI术后2年内血管再通和新病变发生的独立危险因素。对于接受他汀类药物降脂治疗的稳定型心绞痛患者,计算 Esd LDL-C 可为预测血管再通和新病变的发生提供有用信息。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between Estimated Small Dense Low-Density Lipoprotein Cholesterol and Occurrence of New Lesions after Percutaneous Coronary Intervention in Japanese Patients with Stable Angina and Receiving Statin Therapy.

Background: Low-density lipoprotein cholesterol (LDL-C) is considered the most important risk factor for coronary artery disease (CAD). Although lipid-lowering therapy using high-intensity statins for patients with stable CAD is one of the cornerstones of medication therapy, there is still a risk of residual cardiovascular events, even after controlling for LDL-C. Recently, attention has focused on the association between small dense LDL-C as a residual risk factor for CAD, and it has been reported that a formula can be used to calculate the small LDL-C.

Methods: We investigated the association between estimated small dense LDL-C (Esd LDL-C) and the occurrence of new lesions with myocardial ischemia 2 years after percutaneous coronary intervention (PCI) in 537 patients with stable angina who underwent PCI. In this study, all patients had been prescribed statins. This study was based on previously reported data regarding the relationship between non-high-density lipoprotein cholesterol levels and stable angina pectoris after PCI.

Results: Revascularization, including new lesions and in-stent restenosis, and new lesions appeared in 130 and 90 patients, respectively, 2 years after PCI. Age, diabetes mellitus (DM), LDL-C, and Esd LDL-C were associated with the occurrence of revascularization and new lesions 2 years after PCI. Multivariate logistic regression analysis models revealed that Esd LDL-C [odds ratio (OR) 1.03, 95% confidence interval (CI) 1.004-1.048, p = 0.020; and OR 1.03, 95% CI 1.009-1.057, p = 0.007, respectively] were associated with the revascularization and occurrence of new lesions 2 years after PCI.

Conclusions: As well as total cholesterol and LDL-C, Esd LDL-C was an independent risk factor for the revascularization and occurrence of new lesions 2 years after PCI for stable angina in Japanese patients receiving statin therapy. In patients with stable angina who are on lipid-lowering therapy with statins, calculating the Esd LDL-C may provide useful information for predicting revascularization and the occurrence of new lesions.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Reviews in cardiovascular medicine
Reviews in cardiovascular medicine 医学-心血管系统
CiteScore
2.70
自引率
3.70%
发文量
377
审稿时长
1 months
期刊介绍: RCM is an international, peer-reviewed, open access journal. RCM publishes research articles, review papers and short communications on cardiovascular medicine as well as research on cardiovascular disease. We aim to provide a forum for publishing papers which explore the pathogenesis and promote the progression of cardiac and vascular diseases. We also seek to establish an interdisciplinary platform, focusing on translational issues, to facilitate the advancement of research, clinical treatment and diagnostic procedures. Heart surgery, cardiovascular imaging, risk factors and various clinical cardiac & vascular research will be considered.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信